BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vyxeos readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vyxeos\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04990102-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vyxeos: Phase 1/2 readout est. (NCT04990102)
DESCRIPTION:Vyxeos\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Phase IB/I
 I of CPX-351 for Relapse Prevention in AML\nEstimated primary completion: 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vyxeos
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT049
 90102
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156435-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vyxeos: Phase 1 readout est. (NCT07156435)
DESCRIPTION:Vyxeos\, phase 1\, Acute Myeloid Leukemia.\nStudy: Vyxeos® Wit
 h Clofarabine for Pediatric AML\nEstimated primary completion: 31 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/vyxeos#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07156435
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03629171-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vyxeos: Phase 2 readout est. (NCT03629171)
DESCRIPTION:Vyxeos\, phase 2\, Acute Myeloid Leukemia.\nStudy: Liposome-enc
 apsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants 
 With Relapsed\, Refractory or Untreated Acute Myeloid Leukemia\nEstimated 
 primary completion: 31 December 2026. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT03629171
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03826992-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Vyxeos: Phase 1 readout est. (NCT03826992)
DESCRIPTION:Vyxeos\, phase 1.\nStudy: Venetoclax Combined With Vyxeos (CPX-
 351) for Participants With Relapsed or Refractory Acute Leukemia\nEstimate
 d primary completion: January 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT03826992
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04801797-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Vyxeos: Phase 2 readout est. (NCT04801797)
DESCRIPTION:Vyxeos\, phase 2\, Acute Myeloid Leukemia.\nStudy: Venetoclax +
  Azacitidine vs. Induction Chemotherapy in AML\nEstimated primary completi
 on: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/v
 yxeos#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04801797
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05024552-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Vyxeos: Phase 1 readout est. (NCT05024552)
DESCRIPTION:Vyxeos\, phase 1\, Acute Myeloid Leukemia.\nStudy: Vyxeos Plus 
 Gilteritinib in Relapsed or Refractory\, FLT3-Mutated AML\nEstimated prima
 ry completion: 15 February 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/vyxeos#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05024552
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554406-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Vyxeos: Phase 2 readout est. (NCT05554406)
DESCRIPTION:Vyxeos\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing New 
 Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed
  and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)\nEstima
 ted primary completion: 31 March 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05554406
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05558124-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Vyxeos: Phase 1 readout est. (NCT05558124)
DESCRIPTION:Vyxeos\, phase 1\, Acute Myeloid Leukemia.\nStudy: CPX-351 in C
 ombination With Gemtuzumab Ozogamicin in Newly Diagnosed AML\nEstimated pr
 imary completion: April 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/vyxeos#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05558124
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04049539-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Vyxeos: Phase 1/2 readout est. (NCT04049539)
DESCRIPTION:Vyxeos\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Vyxeos for
  Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent
  Disease After Induction\nEstimated primary completion: 31 May 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/vyxeos#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04049539
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03897127-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Vyxeos: Phase 3 readout est. (NCT03897127)
DESCRIPTION:Vyxeos\, phase 3\, Acute Myeloid Leukemia.\nStudy: Study of Sta
 ndard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in
  Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Gene
 tics\nEstimated primary completion: June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03897127
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07008638-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Vyxeos: Phase 1/2 readout est. (NCT07008638)
DESCRIPTION:Vyxeos\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Phase I/II
  Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for th
 e Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)\n
 Estimated primary completion: 30 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07008638
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03896269-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Vyxeos: Phase 1 readout est. (NCT03896269)
DESCRIPTION:Vyxeos\, phase 1.\nStudy: CPX-351 in Treating Patients With Rel
 apsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomon
 ocytic Leukemia\nEstimated primary completion: 31 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/vyxeos#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03896269
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04128748-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Vyxeos: Phase 1/2 readout est. (NCT04128748)
DESCRIPTION:Vyxeos\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Liposomal 
 Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of
  Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome\nEstimated 
 primary completion: 31 December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04128748
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05627232-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Vyxeos: Phase 1 readout est. (NCT05627232)
DESCRIPTION:Vyxeos\, phase 1\, Acute Myeloid Leukemia.\nStudy: Tazemetostat
  and Palbociclib With CPX-351for R/R AML\nEstimated primary completion: Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vyxeos#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT056272
 32
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04493164-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Vyxeos: Phase 2 readout est. (NCT04493164)
DESCRIPTION:Vyxeos\, phase 2\, Acute Myeloid Leukemia.\nStudy: CPX-351 and 
 Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or Hig
 h-Risk Myelodysplastic Syndrome\nEstimated primary completion: 1 June 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/vyxeos#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04493164
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05260528-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20280802
DTEND;VALUE=DATE:20280803
SUMMARY:Vyxeos: Phase 2 readout est. (NCT05260528)
DESCRIPTION:Vyxeos\, phase 2\, Acute Myeloid Leukemia.\nStudy: CPX-351 vs I
 ntensive Chemotherapy in Patients With de Novo Intermediate or Adverse Ris
 k AML Stratified by Genomics\nEstimated primary completion: 2 August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/vyxeos#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05260528
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Vyxeos: Phase 2 readout est. (NCT05564390)
DESCRIPTION:Vyxeos\, phase 2\, Acute Myeloid Leukemia.\nStudy: MYELOMATCH: 
 A Screening Study to Assign People With Myeloid Cancer to a Treatment Stud
 y or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Tr
 ial)\nEstimated primary completion: 15 May 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04293562-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Vyxeos: Phase 3 readout est. (NCT04293562)
DESCRIPTION:Vyxeos\, phase 3\, Acute Myeloid Leukemia.\nStudy: A Study to C
 ompare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib f
 or Patients With Newly Diagnosed AML With or Without FLT3 Mutations\nEstim
 ated primary completion: 30 June 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/vyxeos#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04293562
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554419-2901@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Vyxeos: Phase 2 readout est. (NCT05554419)
DESCRIPTION:Vyxeos\, phase 2\, Acute Myeloid Leukemia.\nStudy: Testing the 
 Use of Combination Therapy in Patients With Persistent Low Level Acute Mye
 loid Leukemia Following Initial Treatment\, The ERASE Study (A MyeloMATCH 
 Treatment Trial)\nEstimated primary completion: 31 December 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/vyxeos#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05554419
URL:https://assetmemo.bio/drug/vyxeos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
